Novel drugs for hypertension and heart failure: struggling for a place under the sun.
|Abstract||Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions.|
Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|Journal Title||current pharmaceutical design|
|Publication Year Start||2017-01-01|
PMID- 28176630 OWN - NLM STAT- Publisher DA - 20170208 LR - 20170208 IS - 1873-4286 (Electronic) IS - 1381-6128 (Linking) DP - 2017 Feb 06 TI - Novel drugs for hypertension and heart failure: struggling for a place under the sun. LID - 10.2174/1381612823666170206154706 [doi] AB - BACKGOUND: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions. METHODS: This review aims to present the pathophysiological basis for the use of these two novel drugs, critically discuss available clinical data, and provide future perspectives. RESULTS: LCZ696 seems a very promising antihypertensive agent, that additionally generates clinically meaningful benefits in patients with heart failure with reduced injection fraction and raises expectations for the management of patients with heart failure with preserved ejection fraction. Finerenone aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria. First available data are very promising for the efficacy of the drug, while it provides a better safety profile than current mineralocorticoid antagonists. CONCLUSION: LCZ696 and finerenone are two novel drugs for the management of arterial hypertension and heart failure. First available data point toward important clinical benefits from their use. Future large trials further investigating the cardiovascular profile of these agents will establish the use of these drugs. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at [email protected] FAU - Faselis, Charles AU - Faselis C AD - VA Medical Center 50 Irving Street, NW Washington, DC 20422,. United States. FAU - Boutari, Chrysoula AU - Boutari C FAU - Doumas, Michael AU - Doumas M FAU - Imprialos, Konstantinos AU - Imprialos K FAU - Stavropoulos, Konstantinos AU - Stavropoulos K FAU - Kokkinos, Peter AU - Kokkinos P LA - eng PT - Journal Article DEP - 20170206 PL - Netherlands TA - Curr Pharm Des JT - Current pharmaceutical design JID - 9602487 OTO - NOTNLM OT - LCZ696 OT - albuminuria OT - diabetic kidney disease OT - finerenone OT - heart failure OT - hypertension OT - mineralocorticoid receptor antagonists OT - neprilysin EDAT- 2017/02/09 06:00 MHDA- 2017/02/09 06:00 CRDT- 2017/02/09 06:00 PHST- 2016/12/13 [received] PHST- 2017/01/19 [revised] PHST- 2017/01/31 [accepted] AID - CPD-EPUB-81551 [pii] AID - 10.2174/1381612823666170206154706 [doi] PST - aheadofprint SO - Curr Pharm Des. 2017 Feb 6. doi: 10.2174/1381612823666170206154706.
<?xml version="1.0" encoding="UTF-8"?> <b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" > </b:Sources>